ID   RINI_HUMAN              Reviewed;         461 AA.
AC   P13489; Q8IZK8; Q96FD7; Q9BQ80; Q9UDK6;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   07-APR-2021, entry version 222.
DE   RecName: Full=Ribonuclease inhibitor;
DE   AltName: Full=Placental ribonuclease inhibitor;
DE            Short=Placental RNase inhibitor;
DE   AltName: Full=Ribonuclease/angiogenin inhibitor 1;
DE            Short=RAI;
GN   Name=RNH1; Synonyms=PRI, RNH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 20-28; 35-44; 47-62; 65-72;
RP   87-130; 147-181; 189-200; 206-226; 231-235; 239-268; 272-276; 288-295;
RP   297-299; 303-316; 353-364; 374-394; 402-412; 424-449 AND 453-461, AND
RP   OXIDATION STATE OF THE CYSTEINES.
RC   TISSUE=Placenta;
RX   PubMed=3219362; DOI=10.1021/bi00423a007;
RA   Lee F.S., Fox E.A., Zhou H.-M., Strydom D.J., Vallee B.L.;
RT   "Primary structure of human placental ribonuclease inhibitor.";
RL   Biochemistry 27:8545-8553(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 444-462.
RX   PubMed=3243277; DOI=10.1002/j.1460-2075.1988.tb03310.x;
RA   Schneider R., Schneider-Scherzer E., Thurnher M., Auer B., Schweiger M.;
RT   "The primary structure of human ribonuclease/angiogenin inhibitor (RAI)
RT   discloses a novel highly diversified protein superfamily with a common
RT   repetitive module.";
RL   EMBO J. 7:4151-4156(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=14515218;
RA   Huang G.H., Yang G.Z., Chen J.Y., Wu X.F.;
RT   "Expression of a human ribonuclease inhibitor variant in Escherichia coli
RT   and silkworm insect cell (Bombyx mori).";
RL   Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 35:960-963(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Colon, Lymph, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-14.
RC   TISSUE=Brain;
RX   PubMed=8037455; DOI=10.1006/abbi.1994.1328;
RA   Nadano D., Yasuda T., Takeshita H., Uchide K., Kishi K.;
RT   "Purification and characterization of human brain ribonuclease inhibitor.";
RL   Arch. Biochem. Biophys. 312:421-428(1994).
RN   [7]
RP   PROTEIN SEQUENCE OF 174-195 AND 288-302, AND INTERACTION WITH RNASE1.
RX   PubMed=1633192; DOI=10.1016/0167-4838(92)90134-y;
RA   Crevel-Thieffry I., Cotterill S., Schuller E.;
RT   "Characterisation of a tryptic peptide from human placental ribonuclease
RT   inhibitor which inhibits ribonuclease activity.";
RL   Biochim. Biophys. Acta 1122:107-112(1992).
RN   [8]
RP   MUTAGENESIS OF SER-461, AND INTERACTION WITH ANG AND RNASE1.
RX   PubMed=9050852; DOI=10.1073/pnas.94.5.1761;
RA   Chen C.Z., Shapiro R.;
RT   "Site-specific mutagenesis reveals differences in the structural bases for
RT   tight binding of RNase inhibitor to angiogenin and RNase A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1761-1766(1997).
RN   [9]
RP   MUTAGENESIS OF 435-TYR-ASP-436, AND INTERACTION WITH ANG AND RNASE1.
RX   PubMed=10413501; DOI=10.1021/bi990762a;
RA   Chen C.Z., Shapiro R.;
RT   "Superadditive and subadditive effects of 'hot spot' mutations within the
RT   interfaces of placental ribonuclease inhibitor with angiogenin and
RT   ribonuclease A.";
RL   Biochemistry 38:9273-9285(1999).
RN   [10]
RP   FUNCTION, MUTAGENESIS OF TRP-262; TRP-264; TRP-319; 435-TYR-ASP-436 AND
RP   SER-461, AND INTERACTION WITH RNASE2.
RX   PubMed=12578357; DOI=10.1021/bi026852o;
RA   Teufel D.P., Kao R.Y., Acharya K.R., Shapiro R.;
RT   "Mutational analysis of the complex of human RNase inhibitor and human
RT   eosinophil-derived neurotoxin (RNase 2).";
RL   Biochemistry 42:1451-1459(2003).
RN   [11]
RP   FUNCTION.
RX   PubMed=17292889; DOI=10.1016/j.febslet.2007.01.072;
RA   Monti D.M., Montesano Gesualdi N., Matousek J., Esposito F., D'Alessio G.;
RT   "The cytosolic ribonuclease inhibitor contributes to intracellular redox
RT   homeostasis.";
RL   FEBS Lett. 581:930-934(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-82, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-91, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 2-461 IN COMPLEX WITH ANG,
RP   INTERACTION WITH ANG, AND DOMAIN.
RX   PubMed=9311977; DOI=10.1093/emboj/16.17.5162;
RA   Papageorgiou A.C., Shapiro R., Acharya K.R.;
RT   "Molecular recognition of human angiogenin by placental ribonuclease
RT   inhibitor -- an X-ray crystallographic study at 2.0-A resolution.";
RL   EMBO J. 16:5162-5177(1997).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 2-461 IN COMPLEX WITH RNASE2,
RP   DOMAIN, INTERACTION WITH RNASE2, AND MUTAGENESIS OF TRP-376 AND ARG-458.
RX   PubMed=15755456; DOI=10.1016/j.jmb.2005.01.035;
RA   Iyer S., Holloway D.E., Kumar K., Shapiro R., Acharya K.R.;
RT   "Molecular recognition of human eosinophil-derived neurotoxin (RNase 2) by
RT   placental ribonuclease inhibitor.";
RL   J. Mol. Biol. 347:637-655(2005).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH RNASE1, DOMAIN, AND
RP   INTERACTION WITH RNASE1.
RX   PubMed=17350650; DOI=10.1016/j.jmb.2007.02.005;
RA   Johnson R.J., McCoy J.G., Bingman C.A., Phillips G.N. Jr., Raines R.T.;
RT   "Inhibition of human pancreatic ribonuclease by the human ribonuclease
RT   inhibitor protein.";
RL   J. Mol. Biol. 368:434-449(2007).
CC   -!- FUNCTION: Ribonuclease inhibitor which inhibits RNASE1, RNASE2 and ANG.
CC       May play a role in redox homeostasis. {ECO:0000269|PubMed:12578357,
CC       ECO:0000269|PubMed:14515218, ECO:0000269|PubMed:17292889}.
CC   -!- SUBUNIT: Forms high-affinity heterodimers with RNASE1, ANG and RNASE2.
CC       {ECO:0000269|PubMed:15755456, ECO:0000269|PubMed:17350650,
CC       ECO:0000269|PubMed:9311977}.
CC   -!- INTERACTION:
CC       P13489; P03950: ANG; NbExp=3; IntAct=EBI-1237106, EBI-525291;
CC       P13489; P07998: RNASE1; NbExp=8; IntAct=EBI-1237106, EBI-2823523;
CC       P13489; O00560: SDCBP; NbExp=8; IntAct=EBI-1237106, EBI-727004;
CC       P13489; O76024: WFS1; NbExp=3; IntAct=EBI-1237106, EBI-720609;
CC       P13489; P61823: RNASE1; Xeno; NbExp=3; IntAct=EBI-1237106, EBI-908364;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- DOMAIN: The LRR domain forms a horseshoe-shaped structure that
CC       interacts tightly with target RNases via a large protein interaction
CC       surface on its interior side. {ECO:0000269|PubMed:15755456,
CC       ECO:0000269|PubMed:17350650, ECO:0000269|PubMed:9311977}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- PTM: At least 30 of the 32 cysteine residues are in the reduced form.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M22414; AAA59130.1; -; mRNA.
DR   EMBL; M36717; AAA60249.1; -; mRNA.
DR   EMBL; X13973; CAA32151.1; -; mRNA.
DR   EMBL; AY071904; AAL60586.1; -; mRNA.
DR   EMBL; AL161967; CAB82310.1; -; mRNA.
DR   EMBL; BC000677; AAH00677.1; -; mRNA.
DR   EMBL; BC003506; AAH03506.1; -; mRNA.
DR   EMBL; BC011186; AAH11186.1; -; mRNA.
DR   EMBL; BC011500; AAH11500.1; -; mRNA.
DR   EMBL; BC014629; AAH14629.1; -; mRNA.
DR   EMBL; BC024037; AAH24037.1; -; mRNA.
DR   EMBL; BC047730; AAH47730.1; -; mRNA.
DR   CCDS; CCDS7697.1; -.
DR   PIR; A31858; A31858.
DR   RefSeq; NP_002930.2; NM_002939.3.
DR   RefSeq; NP_976317.1; NM_203383.1.
DR   RefSeq; NP_976318.1; NM_203384.1.
DR   RefSeq; NP_976319.1; NM_203385.1.
DR   RefSeq; NP_976320.1; NM_203386.2.
DR   RefSeq; NP_976321.1; NM_203387.2.
DR   RefSeq; NP_976322.1; NM_203388.2.
DR   RefSeq; NP_976323.1; NM_203389.2.
DR   RefSeq; XP_011518557.1; XM_011520255.1.
DR   RefSeq; XP_011518559.1; XM_011520257.2.
DR   RefSeq; XP_011518560.1; XM_011520258.2.
DR   RefSeq; XP_011518561.1; XM_011520259.2.
DR   RefSeq; XP_011518562.1; XM_011520260.2.
DR   RefSeq; XP_011518563.1; XM_011520261.2.
DR   RefSeq; XP_011518564.1; XM_011520262.2.
DR   RefSeq; XP_011518565.1; XM_011520263.1.
DR   RefSeq; XP_016873595.1; XM_017018106.1.
DR   PDB; 1A4Y; X-ray; 2.00 A; A/D=2-461.
DR   PDB; 1Z7X; X-ray; 1.95 A; W/Y=1-461.
DR   PDB; 2BEX; X-ray; 1.99 A; A/B=2-461.
DR   PDB; 2Q4G; X-ray; 1.95 A; W/Y=1-461.
DR   PDBsum; 1A4Y; -.
DR   PDBsum; 1Z7X; -.
DR   PDBsum; 2BEX; -.
DR   PDBsum; 2Q4G; -.
DR   SMR; P13489; -.
DR   BioGRID; 111977; 106.
DR   CORUM; P13489; -.
DR   IntAct; P13489; 45.
DR   MINT; P13489; -.
DR   STRING; 9606.ENSP00000433999; -.
DR   iPTMnet; P13489; -.
DR   PhosphoSitePlus; P13489; -.
DR   SwissPalm; P13489; -.
DR   BioMuta; RNH1; -.
DR   DMDM; 132573; -.
DR   REPRODUCTION-2DPAGE; IPI00550069; -.
DR   EPD; P13489; -.
DR   jPOST; P13489; -.
DR   MassIVE; P13489; -.
DR   MaxQB; P13489; -.
DR   PaxDb; P13489; -.
DR   PeptideAtlas; P13489; -.
DR   PRIDE; P13489; -.
DR   ProteomicsDB; 52913; -.
DR   Antibodypedia; 22490; 449 antibodies.
DR   Ensembl; ENST00000354420; ENSP00000346402; ENSG00000023191.
DR   Ensembl; ENST00000356187; ENSP00000348515; ENSG00000023191.
DR   Ensembl; ENST00000397604; ENSP00000380729; ENSG00000023191.
DR   Ensembl; ENST00000397614; ENSP00000380738; ENSG00000023191.
DR   Ensembl; ENST00000397615; ENSP00000380739; ENSG00000023191.
DR   Ensembl; ENST00000438658; ENSP00000416589; ENSG00000023191.
DR   Ensembl; ENST00000533410; ENSP00000435594; ENSG00000023191.
DR   Ensembl; ENST00000534797; ENSP00000433999; ENSG00000023191.
DR   Ensembl; ENST00000612988; ENSP00000479004; ENSG00000276230.
DR   Ensembl; ENST00000617351; ENSP00000484572; ENSG00000276230.
DR   Ensembl; ENST00000618184; ENSP00000478664; ENSG00000276230.
DR   Ensembl; ENST00000619599; ENSP00000479966; ENSG00000276230.
DR   Ensembl; ENST00000621211; ENSP00000480036; ENSG00000276230.
DR   Ensembl; ENST00000632527; ENSP00000487940; ENSG00000276230.
DR   Ensembl; ENST00000632954; ENSP00000487753; ENSG00000276230.
DR   Ensembl; ENST00000633287; ENSP00000488734; ENSG00000276230.
DR   GeneID; 6050; -.
DR   KEGG; hsa:6050; -.
DR   UCSC; uc001lpk.1; human.
DR   CTD; 6050; -.
DR   DisGeNET; 6050; -.
DR   GeneCards; RNH1; -.
DR   HGNC; HGNC:10074; RNH1.
DR   HPA; ENSG00000023191; Low tissue specificity.
DR   MIM; 173320; gene.
DR   neXtProt; NX_P13489; -.
DR   OpenTargets; ENSG00000023191; -.
DR   PharmGKB; PA34447; -.
DR   VEuPathDB; HostDB:ENSG00000023191.16; -.
DR   eggNOG; KOG4308; Eukaryota.
DR   GeneTree; ENSGT00940000161492; -.
DR   HOGENOM; CLU_002274_4_6_1; -.
DR   InParanoid; P13489; -.
DR   OMA; CQLECLW; -.
DR   OrthoDB; 710473at2759; -.
DR   PhylomeDB; P13489; -.
DR   PathwayCommons; P13489; -.
DR   BioGRID-ORCS; 6050; 57 hits in 992 CRISPR screens.
DR   ChiTaRS; RNH1; human.
DR   EvolutionaryTrace; P13489; -.
DR   GeneWiki; RNH1; -.
DR   GenomeRNAi; 6050; -.
DR   Pharos; P13489; Tbio.
DR   PRO; PR:P13489; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P13489; protein.
DR   Bgee; ENSG00000023191; Expressed in skin of leg and 243 other tissues.
DR   ExpressionAtlas; P13489; baseline and differential.
DR   Genevisible; P13489; HS.
DR   GO; GO:0032311; C:angiogenin-PRI complex; IPI:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008428; F:ribonuclease inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0006402; P:mRNA catabolic process; NAS:UniProtKB.
DR   GO; GO:0045765; P:regulation of angiogenesis; IDA:UniProtKB.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR006553; Leu-rich_rpt_Cys-con_subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR041302; LRR_RI_cap.
DR   Pfam; PF13516; LRR_6; 6.
DR   Pfam; PF18779; LRR_RI_capping; 1.
DR   SMART; SM00367; LRR_CC; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing;
KW   Leucine-rich repeat; Phosphoprotein; Reference proteome; Repeat.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:8037455,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..461
FT                   /note="Ribonuclease inhibitor"
FT                   /id="PRO_0000097343"
FT   REPEAT          20..48
FT                   /note="LRR 1"
FT   REPEAT          49..76
FT                   /note="LRR 2"
FT   REPEAT          77..105
FT                   /note="LRR 3"
FT   REPEAT          106..133
FT                   /note="LRR 4"
FT   REPEAT          134..162
FT                   /note="LRR 5"
FT   REPEAT          163..190
FT                   /note="LRR 6"
FT   REPEAT          191..219
FT                   /note="LRR 7"
FT   REPEAT          220..247
FT                   /note="LRR 8"
FT   REPEAT          248..276
FT                   /note="LRR 9"
FT   REPEAT          277..304
FT                   /note="LRR 10"
FT   REPEAT          305..333
FT                   /note="LRR 11"
FT   REPEAT          334..361
FT                   /note="LRR 12"
FT   REPEAT          362..390
FT                   /note="LRR 13"
FT   REPEAT          391..418
FT                   /note="LRR 14"
FT   REPEAT          419..447
FT                   /note="LRR 15"
FT   REGION          2..11
FT                   /note="2 X 5 AA tandem repeats of S-L-D-I-Q"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         82
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         91
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   VARIANT         170
FT                   /note="P -> L (in dbSNP:rs17585)"
FT                   /id="VAR_014726"
FT   MUTAGEN         262
FT                   /note="W->A: Binding affinity decreased 5000-fold over the
FT                   wild type for RNASE2; when associated with A-264 and A-
FT                   319."
FT                   /evidence="ECO:0000269|PubMed:12578357"
FT   MUTAGEN         264
FT                   /note="W->A: Substantially decreased binding affinity for
FT                   RNASE2. Binding affinity decreased 5000-fold over the wild
FT                   type for RNASE2; when associated with A-262 and A-319."
FT                   /evidence="ECO:0000269|PubMed:12578357"
FT   MUTAGEN         319
FT                   /note="W->A: Substantially decreased binding affinity for
FT                   RNASE2. Binding affinity decreased 5000-fold over the wild
FT                   type for RNASE2; when associated with A-262 and A-264."
FT                   /evidence="ECO:0000269|PubMed:12578357"
FT   MUTAGEN         376
FT                   /note="W->A: 40-fold reduction in binding affinity for
FT                   RNASE2."
FT                   /evidence="ECO:0000269|PubMed:15755456"
FT   MUTAGEN         435..436
FT                   /note="YD->AA: Substantially decreases binding affinity for
FT                   RNASE1, ANG and RNASE2."
FT                   /evidence="ECO:0000269|PubMed:10413501,
FT                   ECO:0000269|PubMed:12578357"
FT   MUTAGEN         458
FT                   /note="R->A: 25-fold reduction in binding affinity for
FT                   RNASE2."
FT                   /evidence="ECO:0000269|PubMed:15755456"
FT   MUTAGEN         461
FT                   /note="Missing: A significant decrease in binding affinity
FT                   with RNASE1, slight decrease for the ANG ligand, no real
FT                   change in binding affinity for RNASE2."
FT                   /evidence="ECO:0000269|PubMed:12578357,
FT                   ECO:0000269|PubMed:9050852"
FT   CONFLICT        188
FT                   /note="R -> H (in Ref. 5; AAH03506)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        359
FT                   /note="R -> A (in Ref. 3; AAL60586)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        365
FT                   /note="L -> P (in Ref. 3; AAL60586)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        423..424
FT                   /note="RQ -> SE (in Ref. 2; CAA32151/AAA60249)"
FT                   /evidence="ECO:0000305"
FT   STRAND          3..12
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           17..27
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          31..38
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           42..53
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          60..62
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           69..78
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          89..91
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           99..101
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           102..108
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          117..119
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          122..124
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           126..137
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          146..148
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           156..158
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           159..168
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          174..176
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          179..181
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           183..196
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          203..205
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           215..225
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          231..233
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          236..238
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           240..251
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          260..262
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           270..282
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          288..290
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           297..308
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          310..312
FT                   /evidence="ECO:0007744|PDB:2Q4G"
FT   STRAND          317..319
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           327..329
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           330..339
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          345..347
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          350..352
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           354..365
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          374..376
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           384..396
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          402..404
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          407..409
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           412..422
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          431..433
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   HELIX           441..453
FT                   /evidence="ECO:0007744|PDB:1Z7X"
FT   STRAND          457..460
FT                   /evidence="ECO:0007744|PDB:1Z7X"
SQ   SEQUENCE   461 AA;  49973 MW;  5E88CDAC95BAE5B3 CRC64;
     MSLDIQSLDI QCEELSDARW AELLPLLQQC QVVRLDDCGL TEARCKDISS ALRVNPALAE
     LNLRSNELGD VGVHCVLQGL QTPSCKIQKL SLQNCCLTGA GCGVLSSTLR TLPTLQELHL
     SDNLLGDAGL QLLCEGLLDP QCRLEKLQLE YCSLSAASCE PLASVLRAKP DFKELTVSNN
     DINEAGVRVL CQGLKDSPCQ LEALKLESCG VTSDNCRDLC GIVASKASLR ELALGSNKLG
     DVGMAELCPG LLHPSSRLRT LWIWECGITA KGCGDLCRVL RAKESLKELS LAGNELGDEG
     ARLLCETLLE PGCQLESLWV KSCSFTAACC SHFSSVLAQN RFLLELQISN NRLEDAGVRE
     LCQGLGQPGS VLRVLWLADC DVSDSSCSSL AATLLANHSL RELDLSNNCL GDAGILQLVE
     SVRQPGCLLE QLVLYDIYWS EEMEDRLQAL EKDKPSLRVI S
//
